Wei Zheng

This inventor holds 7 USPTO granted patents and 5 published patent applications and 9 EPO patents. Top assignees: Suzhou Connect Biopharmaceuticals, Ltd., Qualcomm Incorporated. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wei Zheng. Retrieved from https://idiyas.com/inventor/wei-zheng-x760gdeg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 9(Granted Patents)

Company Filing History:

5 out of 5

Suzhou Connect Biopharmaceuticals, Ltd.

patents

2 out of 45,060

Qualcomm Incorporated

patents

Years Active: 2016-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202822 - Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition (2025-01-21),

2. 11866491 - Antibody for binding to interleukin 4 receptor (2024-01-09),

3. 11512078 - Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition (2022-11-29),

4. 10774141 - Antibody for binding to interleukin 4 receptor (2020-09-15),

5. 10280158 - Immune adjustment compound, use thereof and pharmaceutical composition comprising same (2019-05-07),

6. 9645591 - Charge sharing linear voltage regulator (2017-05-09),

7. 9306553 - Voltage level shifter with a low-latency voltage boost circuit (2016-04-05),

Title: Wei Zheng: Innovator in Pharmaceutical Development

Introduction

Wei Zheng is a prominent inventor based in San Diego, CA, known for his contributions to pharmaceutical innovations. He holds a total of 7 patents, showcasing his expertise in developing novel therapeutic solutions.

Latest Patents

Among his latest patents is the "Addition salt of S1P1 receptor agonist and crystal form thereof." This patent discloses a salt form and a crystal form of a drug targeting S1P1 receptor-mediated diseases. The compound, 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazole-3-yl]benzyl}-3-azetidinecarboxylic acid, is designed to treat and prevent symptoms associated with these diseases. Another significant patent is for an "Antibody for binding to interleukin 4 receptor." This invention includes an antibody capable of binding to the IL-4 receptor, along with a nucleic acid sequence encoding the antibody and methods for its production and medical use.

Career Highlights

Wei Zheng has worked with notable companies such as Suzhou Connect Biopharmaceuticals and Qualcomm Incorporated. His experience in these organizations has contributed to his innovative work in the pharmaceutical field.

Collaborations

Wei has collaborated with talented individuals, including Wubin Pan and Xin Yang, enhancing his research and development efforts.

Conclusion

Wei Zheng's contributions to pharmaceutical innovations and his impressive portfolio of patents highlight his significant role in advancing medical science. His work continues to impact the field positively.

Profile summary based on public USPTO records.